SHARE

Wipro Limited (ADR)(NYSE:WIT) reported an association for Quality Engineering. This association with Tricentis will strengthen company’s Quality Engineering and Testing Services features by integrating Tricentis Tosca with Wipro AssureNXT.

The details

The Wipro – Tricentis association will allow customers to successfully achieve their business results in present digital landscape by allowing continuous integration, supply and in turn, DevOps. The offering will also assist enhance quality and time-to-market by amplifying end-to-end automation over the course of the software testing lifecycle.

Hiral Chandrana of Wipro reported that they consider that customers will see this association as a game changer as the two major pioneers in the industry come together to establish a truly disruptive proposition for relentless testing. It will assist them boost speed in their business while resulting in experience and effectiveness to their automation journey via the dominant combination of Wipro AssureNXT, Tricentis Tosca and Wipro HOLMES.

Sandeep Johri, the CEO of Tricentis, reported that as firms increasingly adopt transformation measures, such as DevOps, the dependence on legacy approaches and testing tools are holding firms back, controlling the speed of innovation. Software development has progressed dramatically in the shift from waterfall procedures to Continuous Delivery pipelines. Johri added that software testing must also evolve in order to manage business risks in a faster and flexible manner.

In addition to the partnership deal, Wipro Ventures, which is the strategic investment unit of Wipro Limited, has done an investment in Tricentis, as a major part of their recent funding round.

In the last trading session, the stock price of Wipro declined 0.33% to close the day at $6.13. The decline came at a share volume of 1.61 million compared to average share volume of 1.28 million. After the recent decline, the market cap of firm now stands at $21.64 billion. The 52-week range of stock stands at $4.50 to $6.40.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

https://www.journaltranscript.com/disclaimer

LEAVE A REPLY